Glucagon-like peptide-1 (GLP-1) peptides have emerged as a compelling therapeutic target for managing metabolic conditions. These naturally occurring substances are secreted by the gut in response to nutrient intake, stimulating insulin production and suppressing glucagon release. GLP-1 agents demonstrate promising therapeutic efficacy in treating